Irys's AI-native operating system replaces decades-old systems with scalable, intelligent technology -signaling a new era for insurance distribution modernization and investor confidence in the sector. Irys, the company rebuilding insurance infrastructure from the ground up, today announced a $12.5 million seed round led by Markd, with participation from Deepwork Capital, Florida Opportunity Fund, Ansay & […]
abrdn Global Infrastructure Income Fund (NYSE: ASGI) (“ASGI” or the “Acquiring Fund) and abrdn Japan Equity Fund, Inc. (NYSE: JEQ) (“JEQ” or the “Acquired Fund”), announce today the completed reorganization of the Acquired Fund with the Acquiring Fund after close of business on October 10, 2025. https://mma.prnewswire.com/media/2698388/Aberdeen_Investments_Logo.jpg In the reorganization, common shareholders of JEQ received
Coveo, the leader in AI-Relevance, delivering best-in-class AI-search and generative experiences that maximize business outcomes at every point-of-experience, today announced that it has achieved the Amazon Web Services (AWS) Generative AI Competency. This specialization recognizes Coveo as an AWS Partner that helps customers and the AWS Partner Network (APN) drive the advancement of services, tools,
Multigenerational advisory firm with offices in Washington, Idaho, and Illinois joins Cetera for its technology, personalized service, and commitment to supporting independent financial advisors Cetera today announced the addition of Pillar Financial Group, led by seven partners including CEO Luke Madsen, CFP®, CLU®, and a 34-member advisory team. The Seattle-based firm brings approximately $1.8 billion
(NasdaqGM:MNKD), If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026 WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD)
NEWTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) — Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that members of its leadership team will participate in the 8th Annual Targeted Protein Degradation (TPD) & Induced Proximity Summit, taking place October 27-30, 2025 in Boston,
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes GlobeNewswire October 13, 2025 If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data
Auron Therapeutics to Participate in the 8th Annual Targeted Protein Degradation & Induced Proximity Summit GlobeNewswire October 13, 2025 NEWTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) — Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that members of its leadership team will participate
(AUST:ARR.AX),(OTC US:AMRRY),(OTCQX:AMRRY),(Boerse Frankfurt – Freiverkehr:1BHA),(OTC US:ARRNF),(Other OTC:ARRNF), Highlights Impurity Removal Metallurgical Tests Yield Allanite Rare Earths Processing Breakthrough: Impurity removal is one of the last steps in the hydrometallurgical processing of rare earths elements (“REE”) and is performed to remove non-REE minerals from the leach liquor prior to solvent extraction and separation (i.e. the final
(Milan:RACE),(NYSE:RACE), FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM Maranello (Italy), October 13, 2025 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company“) informs that the Company has purchased, under the Euro 360 million share buyback program announced on July 31, 2025, as the eighth tranche of the multi-year share buyback program of approximately Euro